Celerion is a leader in the evaluation of modified risk tobacco products.
With over 20 years focused on smoking related research, Celerion is uniquely qualified to assist the tobacco industry in bringing their new reduced exposure and modified risk products to market.
Celerion scientists have designed, consulted on, or analyzed data for more than 60 tobacco product-related studies focusing primarily on reducing exposure to harmful tobacco constituents. Celerion is focused on staying abreast of the emerging regulatory changes to enable studies to meet FDA and EMA requirements. Read more
Celerion has conducted approx. 50 clinical studies in the past 15 years to evaluate potential reduced exposure tobacco products and other elements of tobacco biomarker of exposure and effect. Our two purpose-built facilities, strategically located in the US and EU, are equipped to handle the unique requirements specific to tobacco product evaluations. Read more
Celerion’s world leading bioanalytical laboratory offers extensive expertise in the assessment of tobacco constituents, having analyzed over 200,000 samples in the past 3 years. Celerion has made significant investments in the area of tobacco harm reduction research, including a patent pending approach for the testing of e-cigarettes. Read more
Celerion has experience in working with FDA guidelines in the area of tobacco related research and have recently had more exposure to the EMA as well as other regulatory bodies. Leveraging our regulatory experience with our familiarity with the tobacco industry will allow us to assist our clients as they navigate the evolving regulatory pathway toward product approval.